Catalyst
Slingshot members are tracking this event:
Corcept Therapeutics' (CORT) Relacorilant Phase 3 trial expected to start in second half of 2018
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| CORT |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 19, 2018
Occurred Source:
https://ir.corcept.com/news-releases/news-release-details/corcept-therapeutics-announces-first-patient-dosed-phase-3-trial
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Relacorilant, Phase 3 Study, Hypercortisolism
